CoChat
Sign Up
Cited by 112

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Cholesterol‐loaded nanoparticles ameliorate synaptic and cognitive function in Huntington's disease mice

Valenza, Marta, Chen, Jane Y, Di Paolo, Eleonora, Ruozi, Barbara, Belletti, Daniela, Ferrari Bardile, Costanza, Leoni, Valerio, Caccia, Claudio, Brilli, Elisa, Di Donato, Stefano, Boido, Marina M, Vercelli, Alessandro, Vandelli, Maria A, Forni, Flavio, Cepeda, Carlos, Levine, Michael S, Tosi, Giovanni, Cattaneo, Elena·2015·EMBO Molecular Medicine
DOI 10.15252/emmm.201505413PMC PMC4693506
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.201505413

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Reduced striatal DRD2 was consistently demonstrated in patients and murine models and its dysregulation is a sensitive measure of HD pathology.

    “In fact, reduced striatal DRD2 was consistently demonstrated in patients 45,46,47,48,49 and murine models 27,35,50,51 and its dysregulation is a sensitive measure of HD pathology 37 .”

    From SREBP2 gene therapy targeting striatal astrocytes ameliorates Huntington’s disease phenotypes (2021) · cites this paper as [37]

    Citation 37 is attached to the assertion that DRD2 dysregulation is a sensitive measure of HD pathology. The Introduction discusses cholesterol dysregulation, and the Results discuss other synaptic genes, but neither addresses DRD2 as a measure of pathology. Searches for DRD2 and dopamine D2 receptor yielded no passage establishing that point; page numbers were unavailable in our copy. (LLM, conf=0.72)

    Experimental — accuracy not yet measured

  • Downregulation of Drd2 transcript in striatal MSNs is an established early mark of disease progression and has been proposed as a sensitive measure of the effects of therapeutics.

    “Although R6/2 mice (similar to other HD mouse models) do not show overt signs of neuronal loss 26 , the downregulation of Drd2 transcript in striatal MSNs is an established early mark of disease progression that has been proposed as a sensitive measure of the effects of therapeutics 37 .”

    From SREBP2 gene therapy targeting striatal astrocytes ameliorates Huntington’s disease phenotypes (2021) · cites this paper as [37]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 80

  1. Barker GR, Warburton EC (2011) When is the hippocampus involved in recognition memory? J Neurosci 31: 10721–10731 · DOI
  2. Belletti D, Tosi G, Forni F, Gamberini MC, Baraldi C, Vandelli MA, Ruozi B (2012) Chemico‐physical investigation of tenofovir loaded polymeric nanoparticles. Int J Pharm 436: 753–763 · DOI
  3. Cepeda C, Hurst RS, Calvert CR, Hernandez‐Echeagaray E, Nguyen OK, Jocoy E, Christian LJ, Ariano MA, Levine MS (2003) Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J Neurosci 23: 961–969 · DOI · Paper page
  4. Cepeda C, Starling AJ, Wu N, Nguyen OK, Uzgil B, Soda T, Andre VM, Ariano MA, Levine MS (2004) Increased GABAergic function in mouse models of Huntington's disease: reversal by BDNF. J Neurosci Res 78: 855–867 · DOI · Paper page
  5. Chang KH, Wu YR, Chen YC, Chen CM (2015) Plasma inflammatory biomarkers for Huntington's disease patients and mouse model. Brain Behav Immun 44: 121–127 · DOI
  6. Conforti P, Camnasio S, Mutti C, Valenza M, Thompson M, Fossale E, Zeitlin S, MacDonald ME, Zuccato C, Cattaneo E (2013) Lack of huntingtin promotes neural stem cells differentiation into glial cells while neurons expressing huntingtin with expanded polyglutamine tracts undergo cell death. Neurobiol Dis 50: 160–170 · DOI
  7. Costantino L, Gandolfi F, Tosi G, Rivasi F, Vandelli MA, Forni F (2005) Peptide‐derivatized biodegradable nanoparticles able to cross the blood‐brain barrier. J Control Release 108: 84–96 · DOI
  8. Cummings DM, Milnerwood AJ, Dallerac GM, Waights V, Brown JY, Vatsavayai SC, Hirst MC, Murphy KP (2006) Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington's disease. Hum Mol Genet 15: 2856–2868 · DOI
  9. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Preat V (2012) PLGA‐based nanoparticles: an overview of biomedical applications. J Control Release 161: 505–522 · DOI
  10. Darvas M, Palmiter RD (2009) Restriction of dopamine signaling to the dorsolateral striatum is sufficient for many cognitive behaviors. Proc Natl Acad Sci USA 106: 14664–14669 · DOI
  11. Dason JS, Smith AJ, Marin L, Charlton MP (2010) Vesicular sterols are essential for synaptic vesicle cycling. J Neurosci 30: 15856–15865 · DOI
  12. Dason JS, Smith AJ, Marin L, Charlton MP (2014) Cholesterol and F‐actin are required for clustering of recycling synaptic vesicle proteins in the presynaptic plasma membrane. J Physiol 592: 621–633 · DOI
  13. Dietschy JM, Turley SD (2004) Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res 45: 1375–1397 · DOI · Paper page
  14. Frank C, Giammarioli AM, Pepponi R, Fiorentini C, Rufini S (2004) Cholesterol perturbing agents inhibit NMDA‐dependent calcium influx in rat hippocampal primary culture. FEBS Lett 566: 25–29
  15. Frank C, Rufini S, Tancredi V, Forcina R, Grossi D, D'Arcangelo G (2008) Cholesterol depletion inhibits synaptic transmission and synaptic plasticity in rat hippocampus. Exp Neurol 212: 407–414 · DOI
  16. Freeman W, Morton AJ (2004) Regional and progressive changes in brain expression of complexin II in a mouse transgenic for the Huntington's disease mutation. Brain Res Bull 63: 45–55 · DOI
  17. Gabathuler R (2010) Approaches to transport therapeutic drugs across the blood‐brain barrier to treat brain diseases. Neurobiol Dis 37: 48–57 · DOI
  18. Gardoni F, Mauceri D, Malinverno M, Polli F, Costa C, Tozzi A, Siliquini S, Picconi B, Cattabeni F, Calabresi P et al (2009) Decreased NR2B subunit synaptic levels cause impaired long‐term potentiation but not long‐term depression. J Neurosci 29: 669–677 · DOI
  19. Gimpl G, Gehrig‐Burger K (2007) Cholesterol reporter molecules. Biosci Rep 27: 335–358 · DOI
  20. Glynn D, Bortnick RA, Morton AJ (2003) Complexin II is essential for normal neurological function in mice. Hum Mol Genet 12: 2431–2448 · DOI
  21. Gosk S, Vermehren C, Storm G, Moos T (2004) Targeting anti‐transferrin receptor antibody (OX26) and OX26‐conjugated liposomes to brain capillary endothelial cells using in situ perfusion. J Cereb Blood Flow Metab 24: 1193–1204 · DOI
  22. Hara Y, Waters EM, McEwen BS, Morrison JH (2015) Estrogen Effects on Cognitive and Synaptic Health Over the Lifecourse. Physiol Rev 95: 785–807 · DOI · Paper page
  23. HDCRG (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 72: 971–983 · DOI · Paper page
  24. Hering H, Lin CC, Sheng M (2003) Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability. J Neurosci 23: 3262–3271 · DOI
  25. Huttner WB, Zimmerberg J (2001) Implications of lipid microdomains for membrane curvature, budding and fission. Curr Opin Cell Biol 13: 478–484 · DOI
  26. Joshi PR, Wu NP, Andre VM, Cummings DM, Cepeda C, Joyce JA, Carroll JB, Leavitt BR, Hayden MR, Levine MS et al (2009) Age‐dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. J Neurosci 29: 2414–2427 · DOI
  27. Lang T, Bruns D, Wenzel D, Riedel D, Holroyd P, Thiele C, Jahn R (2001) SNAREs are concentrated in cholesterol‐dependent clusters that define docking and fusion sites for exocytosis. EMBO J 20: 2202–2213 · DOI
  28. Lawrence AD, Sahakian BJ, Hodges JR, Rosser AE, Lange KW, Robbins TW (1996) Executive and mnemonic functions in early Huntington's disease. Brain 119(Pt 5): 1633–1645 · DOI
  29. Lawrence AD, Watkins LH, Sahakian BJ, Hodges JR, Robbins TW (2000) Visual object and visuospatial cognition in Huntington's disease: implications for information processing in corticostriatal circuits. Brain 123(Pt 7): 1349–1364 · DOI
  30. Leoni V, Mariotti C, Tabrizi SJ, Valenza M, Wild EJ, Henley SM, Hobbs NZ, Mandelli ML, Grisoli M, Bjorkhem I et al (2008) Plasma 24S‐hydroxycholesterol and caudate MRI in pre‐manifest and early Huntington's disease. Brain 131: 2851–2859 · DOI
  31. Leoni V, Long JD, Mills JA, Di Donato S, Paulsen JS, Group P‐Hs (2013) Plasma 24S‐hydroxycholesterol correlation with markers of Huntington disease progression. Neurobiol Dis 55: 37–43 · DOI
  32. Levine MS, Cepeda C, Hickey MA, Fleming SM, Chesselet MF (2004) Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect. Trends Neurosci 27: 691–697 · DOI
  33. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW et al (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87: 493–506 · DOI · Paper page
  34. Martin MG, Ahmed T, Korovaichuk A, Venero C, Menchon SA, Salas I, Munck S, Herreras O, Balschun D, Dotti CG (2014a) Constitutive hippocampal cholesterol loss underlies poor cognition in old rodents. EMBO Mol Med 6: 902–917 · DOI
  35. Marullo M, Valenza M, Leoni V, Caccia C, Scarlatti C, De MA, Zuccato C, Di Donato S, Carafoli E, Cattaneo E (2012) Pitfalls in the detection of cholesterol in Huntington's disease models. PLoS Curr 4: e505886e505889a501968
  36. Mauch DH, Nagler K, Schumacher S, Goritz C, Muller EC, Otto A, Pfrieger FW (2001) CNS synaptogenesis promoted by glia‐derived cholesterol. Science 294: 1354–1357 · DOI · Paper page
  37. Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD, Ko RW, Vasuta OC, Graham RK, Hayden MR et al (2010) Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron 65: 178–190 · DOI
  38. Milnerwood AJ, Raymond LA (2010) Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease. Trends Neurosci 33: 513–523 · DOI
  39. Minost A, Delaveau J, Bolzinger MA, Fessi H, Elaissari A (2012) Nanoparticles via nanoprecipitation process. Recent Pat Drug Deliv Formul 6: 250–258 · DOI
  40. Morton AJ, Edwardson JM (2001) Progressive depletion of complexin II in a transgenic mouse model of Huntington's disease. J Neurochem 76: 166–172 · DOI
  41. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM (2008) Nano/micro technologies for delivering macromolecular therapeutics using poly(D, L‐lactide‐co‐glycolide) and its derivatives. J Control Release 125: 193–209 · DOI · Paper page
  42. Orth M, Schippling S, Schneider SA, Bhatia KP, Talelli P, Tabrizi SJ, Rothwell JC (2010) Abnormal motor cortex plasticity in premanifest and very early manifest Huntington disease. J Neurol Neurosurg Psychiatry 81: 267–270 · DOI
  43. Paratcha G, Ibanez CF (2002) Lipid rafts and the control of neurotrophic factor signaling in the nervous system: variations on a theme. Curr Opin Neurobiol 12: 542–549 · DOI
  44. Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, MacDonald M, Beglinger LJ et al (2008) Detection of Huntington's disease decades before diagnosis: the Predict‐HD study. J Neurol Neurosurg Psychiatry 79: 874–880 · DOI
  45. Paulsen JS, Long JD (2014) Onset of Huntington's disease: can it be purely cognitive? Mov Disord 29: 1342–1350 · DOI
  46. Paxinos G, Franklin KBJ (2008) Paxinos and Franklin's the Mouse Brain in Stereotaxic Coordinates, 3rd edn. Waltham, MA: Academic Press
  47. Pfrieger FW (2003) Role of cholesterol in synapse formation and function. Biochim Biophys Acta 1610: 271–280 · DOI · Paper page
  48. Reim K, Mansour M, Varoqueaux F, McMahon HT, Sudhof TC, Brose N, Rosenmund C (2001) Complexins regulate a late step in Ca2 + ‐dependent neurotransmitter release. Cell 104: 71–81 · DOI
  49. Renner M, Choquet D, Triller A (2009) Control of the postsynaptic membrane viscosity. J Neurosci 29: 2926–2937 · DOI · Paper page
  50. Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH, Scahill RI, Leavitt BR, Stout JC, Paulsen JS et al (2014) Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 10: 204–216 · DOI · Paper page
  51. Schippling S, Schneider SA, Bhatia KP, Munchau A, Rothwell JC, Tabrizi SJ, Orth M (2009) Abnormal motor cortex excitability in preclinical and very early Huntington's disease. Biol Psychiatry 65: 959–965 · DOI
  52. Sethi A, Sher M, Akram MR, Karim S, Khiljee S, Sajjad A, Shah SN, Murtaza G (2013) Albumin as a drug delivery and diagnostic tool and its market approved products. Acta Pol Pharm 70: 597–600
  53. Shen H, Rodriguez‐Aguayo C, Xu R, Gonzalez‐Villasana V, Mai J, Huang Y, Zhang G, Guo X, Bai L, Qin G et al (2013) Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin Cancer Res 19: 1806–1815 · DOI
  54. Shive MS, Anderson JM (1997) Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 28: 5–24 · DOI · Paper page
  55. Suzuki R, Ferris HA, Chee MJ, Maratos‐Flier E, Kahn CR (2013) Reduction of the cholesterol sensor SCAP in the brains of mice causes impaired synaptic transmission and altered cognitive function. PLoS Biol 11: e1001532 · DOI
  56. Tasciotti E, Liu X, Bhavane R, Plant K, Leonard AD, Price BK, Cheng MM, Decuzzi P, Tour JM, Robertson F et al (2008) Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat Nanotechnol 3: 151–157 · DOI
  57. Thiele C, Hannah MJ, Fahrenholz F, Huttner WB (2000) Cholesterol binds to synaptophysin and is required for biogenesis of synaptic vesicles. Nat Cell Biol 2: 42–49 · DOI · Paper page
  58. del Toro D, Xifro X, Pol A, Humbert S, Saudou F, Canals JM, Alberch J (2010) Altered cholesterol homeostasis contributes to enhanced excitotoxicity in Huntington's disease. J Neurochem 115: 153–167 · DOI
  59. Tosi G, Rivasi F, Gandolfi F, Costantino L, Vandelli MA, Forni F (2005) Conjugated poly(D, L‐lactide‐co‐glycolide) for the preparation of in vivo detectable nanoparticles. Biomaterials 26: 4189–4195 · DOI
  60. Tosi G, Costantino L, Rivasi F, Ruozi B, Leo E, Vergoni AV, Tacchi R, Bertolini A, Vandelli MA, Forni F (2007) Targeting the central nervous system: in vivo experiments with peptide‐derivatized nanoparticles loaded with Loperamide and Rhodamine‐123. J Control Release 122: 1–9 · DOI
  61. Tosi G, Costantino L, Ruozi B, Forni F, Vandelli MA (2008) Polymeric nanoparticles for the drug delivery to the central nervous system. Expert Opin Drug Deliv 5: 155–174 · DOI
  62. Tosi G, Vergoni AV, Ruozi B, Bondioli L, Badiali L, Rivasi F, Costantino L, Forni F, Vandelli MA (2010) Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: in vivo pharmacological evidence and biodistribution. J Control Release 145: 49–57 · DOI
  63. Tosi G, Bondioli L, Ruozi B, Badiali L, Severini GM, Biffi S, De Vita A, Bortot B, Dolcetta D, Forni F et al (2011a) NIR‐labeled nanoparticles engineered for brain targeting: in vivo optical imaging application and fluorescent microscopy evidences. J Neural Transm 118: 145–153 · DOI
  64. Tosi G, Fano RA, Bondioli L, Badiali L, Benassi R, Rivasi F, Ruozi B, Forni F, Vandelli MA (2011b) Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood‐brain barrier. Nanomedicine 6: 423–436 · DOI
  65. Tosi G, Badiali L, Ruozi B, Vergoni AV, Bondioli L, Ferrari A, Rivasi F, Forni F, Vandelli MA (2012) Can leptin‐derived sequence‐modified nanoparticles be suitable tools for brain delivery? Nanomedicine 7: 365–382 · DOI
  66. Tosi G, Vilella A, Chhabra R, Schmeisser MJ, Boeckers TM, Ruozi B, Vandelli MA, Forni F, Zoli M, Grabrucker AM (2014) Insight on the fate of CNS‐targeted nanoparticles. Part II: intercellular neuronal cell‐to‐cell transport. J Control Release 177: 96–107 · DOI · Paper page
  67. Trager U, Andre R, Magnusson‐Lind A, Miller JR, Connolly C, Weiss A, Grueninger S, Silajdzic E, Smith DL, Leavitt BR et al (2014) Characterisation of immune cell function in fragment and full‐length Huntington's disease mouse models. Neurobiol Dis 73C: 388–398
  68. Trushina E, Singh RD, Dyer RB, Cao S, Shah VH, Parton RG, Pagano RE, McMurray CT (2006) Mutant huntingtin inhibits clathrin‐independent endocytosis and causes accumulation of cholesterol in vitro and in vivo. Hum Mol Genet 15: 3578–3591 · DOI
  69. Trushina E, Canaria CA, Lee DY, McMurray CT (2014) Loss of caveolin‐1 expression in knock‐in mouse model of Huntington's disease suppresses pathophysiology in vivo. Hum Mol Genet 23: 129–144 · DOI
  70. Valenza M, Rigamonti D, Goffredo D, Zuccato C, Fenu S, Jamot L, Strand A, Tarditi A, Woodman B, Racchi M et al (2005) Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J Neurosci 25: 9932–9939 · DOI · Paper page
  71. Valenza M, Cattaneo E (2006) Cholesterol dysfunction in neurodegenerative diseases: is Huntington's disease in the list? Prog Neurobiol 80: 165–176 · DOI
  72. Valenza M, Carroll JB, Leoni V, Bertram LN, Bjorkhem I, Singaraja RR, Di Donato S, Lutjohann D, Hayden MR, Cattaneo E (2007a) Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation. Hum Mol Genet 16: 2187–2198 · DOI · Paper page
  73. Valenza M, Leoni V, Tarditi A, Mariotti C, Bjorkhem I, Di Donato S, Cattaneo E (2007b) Progressive dysfunction of the cholesterol biosynthesis pathway in the R6/2 mouse model of Huntington's disease. Neurobiol Dis 28: 133–142 · DOI · Paper page
  74. Valenza M, Leoni V, Karasinska JM, Petricca L, Fan J, Carroll J, Pouladi MA, Fossale E, Nguyen HP, Riess O et al (2010) Cholesterol defect is marked across multiple rodent models of Huntington's disease and is manifest in astrocytes. J Neurosci 30: 10844–10850 · DOI · Paper page
  75. Valenza M, Marullo M, Di Paolo E, Cesana E, Zuccato C, Biella G, Cattaneo E (2015) Disruption of astrocyte‐neuron cholesterol cross talk affects neuronal function in Huntington's disease. Cell Death Differ 22: 690–702 · DOI · Paper page
  76. Vergoni AV, Tosi G, Tacchi R, Vandelli MA, Bertolini A, Costantino L (2009) Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution. Nanomedicine 5: 369–377 · DOI
  77. Vilella A, Tosi G, Grabrucker AM, Ruozi B, Belletti D, Vandelli MA, Boeckers TM, Forni F, Zoli M (2014) Insight on the fate of CNS‐targeted nanoparticles. Part I: Rab5‐dependent cell‐specific uptake and distribution. J Control Release 174: 195–201 · DOI
  78. Vonsattel JP, DiFiglia M (1998) Huntington disease. J Neuropathol Exp Neurol 57: 369–384 · DOI
  79. Zuccato C, Valenza M, Cattaneo E (2010) Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 90: 905–981 · DOI · Paper page
  80. Zuccato C, Cattaneo E (2014) Huntington's disease. Handb Exp Pharmacol 220: 357–409 · DOI

Cited by

Sorted by citations

Metadata

Authors
Valenza, M., Chen, J. Y., Di Paolo, E., Ruozi, B., Belletti, D., Ferrari Bardile, C., Leoni, V., Caccia, C., Brilli, E., Di Donato, S., Boido, M. M., Vercelli, A., Vandelli, M. A., Forni, F., Cepeda, C., Levine, M. S., Tosi, G., & Cattaneo, E.
Venue
EMBO Molecular Medicine
Publisher
Springer Science and Business Media LLC
Published
2015-11-20
Volume
7
Issue
12
Pages
1547-1564
ISSN
  • 1757-4676
  • 1757-4684
DOI
10.15252/emmm.201505413
PMC
PMC4693506
Cited by
112
References
5
Language
en
Licence
Funders
  • Neuromics European (305121)
  • Ministero della Salute under 40 (GR‐2008‐1145270)
  • USPHS (NS41574, HD004612, NS081335)
  • The Hereditary Disease Foundation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review